

PUBLICATIONS

1. 967: Bone marrow sparing extended field CRT with ddNACT in Stage IIIC2 carcinoma cervix: a phase II study. N Das, SK Saini, DN Sharma, K Kamboj, S Khurana, S.A. Shamim, Raja Pramanik, Dhanabalan Rajasekaran, **Babita Kataria**, Danda Vamsi Sai Praveen, Swayamjeet Sathapathy. Radiotherapy and Oncology, 2024
2. Sharma A, Upadhy S, Khurana S, D. Pushpam, S. Kumar, D. Jain, S. Thulkar, A. Kumar, **B. Kataria**, N.K. Gupta, J. Saikia, A. Singhal, A. Nambirajan, P.S. Malik. EP.14A.14 Clinical Insights and Survival Outcomes of Malignant Pleural Mesothelioma: An Experience from a Tertiary Care Centre in India. Journal of Thoracic Oncology. 2024;19(10, Supplement):S689. doi:<https://doi.org/10.1016/j.jtho.2024.09.1306>
3. Manav, N., Jit, B. P., **Kataria, B.**, & Sharma, A. (2024). Cellular and epigenetic perspective of protein stability and its implications in the biological system. Epigenomics, 16(11–12), 879–900. <https://doi.org/10.1080/17501911.2024.2351788>.
4. Sarita Kumari, Carolin Solomi, **Babita Kataria**, Neerja Bhatla. Metastatic involvement of lesser omentum and types of omentectomy in epithelial ovarian cancer. Journal of Gynecologic oncology. <https://doi.org/10.3802/jgo.2024.35.S1.0229>.
5. Manav N, Jit BP, **Kataria B**, Sharma A. Cellular and epigenetic perspective of protein stability and its implications in the biological system. Epigenomics. 2024 June; :1-22.
6. Khan S, Das A, Vashisth D, Mishra A, Vidyarthi A, Gupta R, Begam N, **Kataria B**, Bhatnagar S. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales. PLOS ONE. 2024-5-; 19(5): e0303753-. doi: 10.1371/journal.pone.0303753.
7. Khan S, Kharchandy H, **Kataria B***. Metronidazole Refractory Giardiasis Complicating the Management of Rhabdomyosarcoma in a Child. Journal of Antimicrobial Stewardship Practices and Infectious diseases. 2024 March; 2(1):15-19. doi: 10.62541/jaspi017.
8. Khan S, Das A, **Kataria B**, Yadav H, Mirdha BR. Nitazoxanide refractory cryptosporidiosis complicating Burkitt lymphoma in a child. Trop Parasitol. 2024 Jan-Jun;14(1):50-53. doi: 10.4103/tp.tp_25_23. Epub 2024 Feb 15. PubMed PMID: 38444792; PubMed Central PMCID: PMC10911182.
9. Sharma V, Kumar A, Baa A, Kirar S, Sharma A, Bakhshi S, Gogia A, Malik PS, Rastogi S, Batra A, Pushpam D, **Kataria B**, Sagiraju H, Sharma A, Singh V. Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study. BMJ Support Palliat Care. 2024 Jan 8;13(e3): e867-e871. doi: 10.1136/spcare-2022-003864. PubMed PMID: 36927873.
10. Ravindra SG, Pathak J, Khan D, Garg S, Khurana A, Das KJ, **Kataria B**. Unusual Male Breast Involvement in Burkitt Lymphoma Detected on Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Indian J Nucl Med. 2023 Jul-Sep;38(3):301-302. doi: 10.4103/ijnm.ijnm_8_23. Epub 2023 Oct 10. PubMed PMID: 38046971; PubMed Central PMCID: PMC10693359.
11. Vidyarthi A, Khan S, **Kataria B**, Nandal M, Phogat V, Das A, Chaudhry R. Chryseobacterium Bloodstream Infection in a Case of Non-Hodgkins Lymphoma: An Emerging Pathogen Complicating Clinical Management in Cancer Patients. Journal of Pure and Applied Microbiology. 2023-9-; 17(3):1422-1428. doi: 10.22207/JPAM.17.3.05.

12. BM M, kumar A, Batra A, Sharma V, **Kataria B**, Gogia A, Mathur S, Sharma A. Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH). American Society of Clinical Oncology; 2023. 0732-183X.
13. Kumar A, Baghmar S, Mehta P, Tiwari P, Kumar L, Bakhshi S, Agarwal A, Gupta I, Trikha A, Bhatnagar S, Gogia A, Malik PS, Sahoo RK, Rastogi S, Pramanik R, Batra A, Pushpam D, Sharma CK, Sharma V, **Kataria B**, Goyal K, Samaga S, Bothra SJ, Sharma A. Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from India. Indian J Med Res. 2022 May-Jun;155(5&6):546-553. doi: 10.4103/ijmr.ijmr_1703_21. PubMed PMID: 36348601; PubMed Central PMCID: PMC9807197.
14. **Kataria B**, Sharma A, Pramanik R, Sahoo R, Thulkar S, Yadav M, Mishra S, Prasad C, Vishnubhatla S. PD-9 Three-arm phase II/III randomized controlled trial in patients with unresectable/metastatic gall bladder cancer with poor performance status: Erlotinib or capecitabine v/s best supportive care. Annals of Oncology. 2022; 33: S242.
15. Bhargave S, Kumar A, Sharma V, **Kataria B**, Pushpam D, Batra A, Pramanik R, Khurana S, Sahoo R, Malik P. Olanzapine versus fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC \geq 4) containing chemotherapy regimen: A phase 3 randomized, double-blind, placebo-controlled trial. American Society of Clinical Oncology; 2022. 0732-183X.
16. Sharma A, **Kataria B**¹, Biswas B, Bakhshi S, Pushpam D. Oral metronomic chemotherapy is a cost-effective alternative to pazopanib in advanced soft tissue sarcoma. J Oncol Pharm Pract. 2022 Apr;28(3):560-568. doi: 10.1177/10781552211000113. Epub 2021 Mar 9. PubMed PMID: 33719725.
17. **Kataria B**, Sharma A, Biswas B, Bakhshi S, Pushpam D. Pazopanib in rare histologies of metastatic soft tissue sarcoma. Ecancermedicalsecience. 2021; 15:1281. doi: 10.3332/ecancer.2021.1281. eCollection 2021. PubMed PMID: 34824604; PubMed Central PMCID: PMC8580588.
18. Prasad KT, Muthu V, Biswas B, Malik PS, Dabkara D, Ganguly S, Ghosh J, **Kataria B**, Khurana S, Verma S, Singh N. Utility and safety of maintenance chemotherapy in advanced non-small cell lung cancer across various performance status categories: real-world experience. Curr Probl Cancer. 2020 Jun;44(3):100565. doi: 10.1016/j.crrprblcancer.2020.100565. Epub 2020 Mar 5. PubMed PMID: 32173058.
19. Kumar L, Ramavath D, **Kataria B**, Tiwari A, Raj A, Chellapuram SK, Mookerjee A, Sahoo RK, Malik PS, Sharma A, Gupta R, Sharma OD, Biswas A, Kumar R, Thulkar S. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Indian J Med Res. 2019 Jun;149(6):730-739. doi: 10.4103/ijmr.IJMR_1593_18. PubMed PMID: 31496525; PubMed Central PMCID: PMC6755776.
20. **Kataria B***, Sharma A, Mishra S, Bhatnagar S, Thulkar S, Yadav M, Sahoo R, Pramanik R, Prasad C, Sreenivas V. Capecitabine+ best supportive care (BSC) or erlotinib+ BSC has overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT). Annals of Oncology. 2019; 30: v279.
21. **Kataria B***, Upadhyay A, Kumar L. Stop Imatinib: Real World Data from a Tertiary Care Center in India. Clinical Lymphoma, Myeloma and Leukemia. 2019; 19: S301.

22. Rastogi S, Aggarwal A, Soti K, Vanidassane I, Sharma M, Yadav A, Sharma A, **Kataria B**, Deo S. Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. American Society of Clinical Oncology; 2017. 0732-183X.
23. Kutiya AS, Dharmshaktu P, **Kataria B**, Garg A. A Rare Occurrence of Simultaneous Venous and Arterial Thromboembolic Events - Lower Limb Deep Venous Thrombosis and Pulmonary Thromboembolism as Initial Presentation in Acute Promyelocytic Leukemia. Clin Med Insights Oncol. 2016; 10:1-4. doi: 10.4137/CMO.S37866. eCollection 2016. PubMed PMID: 26949347; PubMed Central PMCID: PMC4768938.
24. Dhanwal D, **Kataria B**, Kumar V. Secondary fracture prevention-a New Delhi, India initiative. OSTEOPOROSIS INTERNATIONAL. 2013; 24: S60-S60.